INDEVUS Pharmac. - die 500% Chance u.a. mit dem Aids Medikament Pro Gel 2000!!!! - 500 Beiträge pro Seite

[Wallgrekk]

Hallo!

Ich möchte die Gelegenheit nutzen, einen neuen Thread zu eröffnen, da das letzte Posting bereits über 4 Wochen zurückliegt.

Falls noch niemand diese Aktie kennt, hier gibt es eine riesen Möglichkeit innerhalb weniger Zeit (mittelfristig) einen guten Schnitt zu machen.

Vielleicht einige Worte zu der Aktie:

Indevus (vorher Interneuron) hatte vor einigen Jahren einen sehr heftigen Rechtsstreit mit AHP. Dieser wurde zu Gunsten Indevus entschieden und dadurch erhielt Indevus eine Meilensteinzahlung von mehreren Mio $. Die Produktpipeline von Indevus ist enorm!
Eines der besten Produkte von Indevus ist das Medikament "Pagoclone", welches eigentlich von Pfizer hätte abgekauft werden sollen. Die Vorverträge waren schon unterschrieben und Indevus konnte während dieser Verhandlungen von $4 auf knapp $13 steigen!

Leider wurde in letzter Sekunde das Medikament von Pfizer aufgrund eigener Ergebnisse abgewiesen und Indevus verlor schlagartig über 90% an Wert!!

Indevus hat momentan mehr als $50 mio. Cash! und ist bei diesem Kurs WEIT unterbewertet! Phantasie kommt momentan auf während des AIDS Kongress in Barcelona, wird doch T-20 (Roche) als ein bahnbrechendes Medikament in Sachen Bekämpfung von AIDS gepriesen.

Indevus hat ein ebenfalls sehr starkes Medikament für die AIDS Bekämpfung in der Pipeline: PRO GEL 2000. Das ist ein Gel, welches auf die weiblichen Geschlechtsorgane aufgetragen wird und das Eindringen von AIDS Viren verhindert. Soweit ich informiert bin, ist PRO GEL 2000 bereits in Phase III und wird auf dem momentan noch laufenden AIDS Kongress in Barcelona vorgestellt.

Hier der Kursverlauf:







Die letzte News vom 01.07.02 ist ebenfalls sehr sehr gut, in dieser werden auch noch mal kurz alle wichtigen Produkte von Indevus beschrieben:

Contact at [phone]:
Michael Rogers
EVP, CFO and Treasurer

William B. Boni
Vice President, Corporate Communications
[phone]


LEXINGTON, MA, July 1, 2002 -- Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today announced that it has licensed exclusive worldwide rights from Atlantic Technology Ventures, Inc. (OTC BB:ATLC.OB) to CT-3, a novel anti-inflammatory and analgesic compound currently in clinical development.

CT-3, a new chemical entity also known as ajulemic acid, is a non-psychoactive synthetic derivative of tetrahydrocannabinol (THC). The principle mechanism of action of the compound appears to be the potent inhibition of the inflammatory cytokines, particularly interleukin-1ß and TNF-alpha. The compound has significant activity in multiple pre-clinical models of pain and inflammation. Unlike most available non-steroidal anti-inflammatory agents (NSAIDS), in pre-clinical studies CT-3 does not appear to produce gastrointestinal ulceration.

An IND (investigational new drug application) has been filed with the U.S. Food and Drug Administration (FDA) for CT-3, and an initial Phase 1 clinical trial designed to assess the safety of CT-3 showed that it was well tolerated, with no clinically significant adverse events and no evidence of psychotropic activity. The compound is currently being studied in Europe in a small Phase II study in patients with chronic neuropathic pain.

“We are excited about the potential of a novel potent NSAID which lacks the ulcerogenic effects of traditional compounds,” said Glenn L. Cooper, M.D. chairman, president and chief executive officer of Indevus. “CT-3 has the potential to be an important new medication for painful inflammatory conditions such as arthritis, post-operative pain, musculoskeletal injuries, headache and neuropathic pain. Furthermore, the compound possesses activity in preclinical models of multiple sclerosis and the cutaneous inflammation associated with exposure to the chemical warfare blister agent sulfur mustard. The U.S. Army Medical Research Institute is pursuing further work on this important application. The overall field of inflammation and pain management is large and not fully satisfied, and we believe a compound such as CT-3 may have broad applications in these major markets.”

The acquisition of CT-3 by Indevus includes an up-front licensing payment, development milestones and royalty payments from Indevus to Atlantic. Indevus is responsible for the clinical development, regulatory activities and commercialization of this compound. A director of Indevus is a shareholder of Atlantic Technology Ventures. The transaction was approved by all of the disinterested directors of Indevus.

Atlantic Technology Ventures is a biopharmaceutical company engaged in the development of biomedical and pharmaceutical products and related technologies for use in cancer, infection, ophthalmic disorders, pain and inflammation and dermatological conditions. Atlantic`s strategy is to identify nascent medical products and technologies that have the potential to address unmet market needs, rapidly develop these through a definitive proof-of-principle, then partner, license or sell them to realize significant revenue.

Status of additional Indevus products

CT-3 is the latest addition to the Indevus product portfolio, which also includes: trospium, in Phase III for overactive bladder; pagoclone, in Phase III for panic disorder and Phase II for generalized anxiety disorder; PRO 2000, in Phase II for the prevention of the sexual transmission of HIV; dersalazine, in Phase I for inflammatory bowel disease; and citicoline for stroke, which has completed several Phase III clinical trials.

Trospium

As recently announced, enrollment has been completed in a Phase III, 524-patient clinical trial with trospium in overactive bladder. The co-primary endpoints of the trial are the comparisons of the reduction in the frequency of urination and the reduction in incontinence episodes among trospium-treated patients versus placebo patients. Data from this trial is expected in the fall, and assuming a positive outcome, the Company expects to file a New Drug Application for trospium by the end of 2002. This data will expand the current clinical trial database for trospium, which comprises over 2200 patients in Europe. European trials include two double-blind, placebo-controlled dose-ranging studies, five double-blind, placebo-controlled studies and several comparative trials, one of which was a long-term comparative 52-week study on safety, tolerability and efficacy.

Pagoclone

Following the return of exclusive, worldwide rights to pagoclone from Pfizer Inc on June 7, 2002, Indevus has initiated corporate partnering discussions for this compound. Decisions regarding the continued clinical development and partnering of pagoclone for generalized anxiety and panic disorders will be based on additional analyses of a total data package from six clinical trials and will include ongoing consultation with Aventis, S.A., licensor of this drug. Aventis has a contractual right for a period of 90 days from the termination of the agreement between Pfizer and Indevus to elect to develop pagoclone under the terms established in that agreement.

Dersalazine

Dersalazine, for inflammatory bowel disease, is undergoing Phase I clinical testing in the U.K. Plans for future Phase II testing in ulcerative colitis will be dependent on the successful completion of this trial.

Citicoline

Two important meta-analyses of clinical trials with citicoline presented at the 27th International Stroke Conference in February 2002 suggest that treatment with this drug may reduce infarct growth after stroke and reduce rates of death or disability over a long term. The first of these analyses retrospectively analyzed seven controlled trials enrolling 1,963 patients who received oral or intravenous citicoline at doses ranging from 500 to 2000 milligrams daily and showed that treatment with citicoline was associated with a significant reduction in rates of death or disability at long-term follow-up. On a combined basis across these trials, 54.6 percent of citicoline patients experienced death or disability, compared with 66.4 percent of placebo patients, p<0.00001.

The second of these analyses retrospectively analyzed data regarding infarct growth following stroke from two clinical trials in a total of 214 patients. Doses of 500 milligrams/day and 2000 milligrams/day were used in these trials. The mean volume increase in infarct size was 84.7 percent for the placebo group, 34.0 percent for the 500 milligram group and 1.8 percent for the 2,000 milligram group, p=0.015. As a result of corporate partnering interest following these findings, Indevus has signed a non-binding memorandum of agreement with a privately held biotechnology company to fund the further development of citicoline. The finalization of this agreement is contingent upon the negotiation of a definitive contract and agreement on the design and clinical endpoints of an additional large Phase III trial.

PRO 2000

Government agencies in the U.S. and the U.K. have selected PRO 2000, a topical microbicide to prevent the sexual transmission of HIV, for testing in large, logistically complex Phase II and Phase III trials planned to begin in 2002 and 2003. The U.K.’s Department for International Development provided the most recent financial support for the clinical testing of PRO 2000 through a grant of approximately $22.7 million made to an international research collaboration.

Indevus Pharmaceuticals is engaged in the development and commercialization of a portfolio of products and product candidates, including multiple compounds in late-stage clinical development. The Company`s lead products under development include trospium for overactive bladder, pagoclone for panic/anxiety disorders, PRO 2000 for the prevention of infection by HIV and other sexually transmitted pathogens, and dersalazine for inflammatory bowel disease.



Bei einem derzeitgen Kurs von $1.15 also aus meiner Sicht ein absolutes "Strong Buy"!!!

Es wird nicht mehr lange dauern, bis sich Indevus auf mind. $2.0 hochschieben wird!


Viel Spaß mit der Aktie,

Wall

[Wallgrekk]

Hier vielleicht noch die WKN: 883147

[Cosmicpalm]

ganz interessant... kannst du denn auch erklären warum die Aktie Anfang Juni so abgestürzt ist??

[Voltaires]

Hallo,

kurz vor dem 7.9. wird´s spannend. Denn Aventis hat 90 Tage (seit dem 7.6.) Zeit, die forschung von Pagoclone zu übernehmen. Wenn sie´s machen, geht´s locker wieder rauf auf 5-6$. Wenn nicht, machen wir ein langes Gesicht.

so long
Voltaires

[Wallgrekk]

Cosmicpalm:

Habe ich doch bereits geschrieben: Das Medikament "Pagoclone" wurde in letzter Sekunde von Pfizer abgelehnt!

[Wallgrekk]

Hi Voltaires!

Immer noch long mit IDEV? Ich komm nicht umhin, aber die Aktie ist für mich momentan unter den Top3 der interessantesten Investments EVER!!

Kannst Du mir genauere Infos über Aventis geben? Ich hab das gar nicht so mitbekommen...

Danke!!

[Voltaires]

@ wallkrekk
By Ann Keeton
Of DOW JONES NEWSWIRES

CHICAGO (Dow Jones)--Shares of drug developer Indevus Pharmaceuticals Inc.
(IDEV) fell 80% Friday after the company said Pfizer Inc. (PFE) had dropped
clinical trials on pagoclone, Indevus`s drug treatment for generalized anxiety
disorder and panic disorder.
Shares traded recently at $1.08 on volume of 7.2 million compared with
average daily volume of 259,200. The shares fell to a new low of 85 cents
earlier; the previous low of $3.65 was reached Sept. 21.
"Clearly, the market had its hopes pinned on pagoclone," said analyst Martin
Auster at SunTrust Robinson Humphrey. Now that Pfizer has returned all
development rights on the drug to Indevus, "it won`t have the $1 billion
potential that we were hoping for," Auster said. Even though Pfizer said
pagoclone didn`t meet Pfizer`s goals in recent trials for treating anxiety and
panic disorders with fewer side effects than other drugs, there may still be a
market for the drug, Auster said.


French drug-maker Aventis S.A.(AVE) has some licensing rights to the drug,
and now has 90 days to decide if it wants to participate in future
development. If Aventis declines to go forward with pagoclone "Indevus could
shop it to other drug makers.

It could be that it will work for just for panic
disorder, and not for both anxiety and panic," Auster said.
Still, Auster - who said he is barred by his employer from buying stock in
companies he covers - said he is maintaining a buy rating on the shares. "The
company now has a market cap that is less than its cash value - it has $50
million in cash," he said.
Auster said Indevus has another promising drug in the pipeline, trospium, for
treating overactive bladder. Trospium could get FDA approval by the end of
this year or the beginning of 2003, he said.
The analyst sees the pagoclone-related selloff as "a great opportunity for
individual investors. The company is now too small for funds to buy into it,
but as a small investor, I`d be all over the stock."
In a research note Friday, Auster said, "I am cutting my price target to $6
from $15. I think it will recover to the $3 to $4 level, which is fair value
for the stock, in a few months. In 12 to 18 months, it can go to $6."

So long.
V.

[Wallgrekk]

@Voltaires:

Klasse! Danke herzlichst. Weißt Du zufällig auch mehr wie Stand der Dinge in Barcelona ist?

LG,

Wall

[Wallgrekk]

Nasdaq bereits +7.2%!

[Wallgrekk]

Am 08.08.02 sollen

die Zahlen kommen...!

[Voltaires]

@ all

hier sind sie:
http://biz.yahoo.com/bw/020809/92068_1.html
Nicht gerade berauschend, aber nicht kursrelevant. Aber was zählt, ist Aventis. also max. noch einen Monat warten ...

So long.
V.

[Wallgrekk]

Hi Voltaires,

yepp, beim Kurs tut sich (noch) nix.

Also auf AVENTIS Entscheidung warten.

Schade.

Hier für alle zum mitlesen:

Friday August 9, 9:02 am Eastern Time
Press Release
SOURCE: Indevus Pharmaceuticals
Indevus Pharmaceuticals Announces Third Quarter Fiscal 2002 Results
LEXINGTON, Mass.--(BW HealthWire)--Aug. 9, 2002--Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV - News) today announced the consolidated results of its operations for the three and nine-month periods ended June 30, 2002. ADVERTISEMENT




The Company reported a net loss of $6,015,000, or $0.13 per share diluted, for the three-month period ended June 30, 2002, compared with net income of $4,300,000, or $0.09 per share diluted, for the three-month period ended June 30, 2001. For the nine-month period ended June 30, 2002, the Company reported a net loss of $12,769,000, or $0.28 per share diluted, versus a net loss of $9,442,000 or $0.21 per share diluted, for the nine-month period ended June 30, 2001. Results for the three and nine-month periods ended June 30, 2002 include significant expenses for the Company`s ongoing Phase III trial for trospium.

At June 30, 2002, the Company had cash, cash equivalents and marketable securities of approximately $46,443,000.

"During the third quarter of fiscal 2002, patient enrollment was completed in the Company`s Phase III trial with trospium in overactive bladder," said Glenn L. Cooper, M.D., chairman, president and chief executive officer of Indevus. "The 12-week, double-blind, placebo-controlled trial includes 524 patients enrolled at over 50 clinical sites in the U.S. Data from this trial is expected in the fall of 2002, and assuming a positive outcome, the Company expects to file a New Drug Application for trospium as soon as practicable thereafter.

"Following the return of exclusive, worldwide rights to pagoclone from Pfizer Inc in June 2002, we have conducted additional analyses of the total data package from six clinical trials with pagoclone," said Dr. Cooper. "These data, combined with extensive clinical pharmacology, manufacturing process and commercial formulation work completed to date, represent significant value and underscore the potential of pagoclone as a novel anti-anxiety agent. Aventis, S.A., which originally licensed pagoclone to the Company, has an option to reacquire the rights to pagoclone under the same terms as those in the Pfizer agreement. Aventis is currently reviewing the pagoclone data package. The Company will initiate additional partnering discussions should Aventis choose not to move forward with pagoclone development.

"In July 2002, Indevus expanded its product pipeline with the licensing of exclusive, worldwide rights to CT-3, a novel anti-inflammatory and analgesic compound," said Dr. Cooper. "CT-3 has shown significant activity in several pre-clinical models of pain and inflammation. An initial Phase I clinical trial showed that CT-3 was well tolerated, and the compound is currently being studied in Europe in a small Phase II study in patients with chronic pain. We believe CT-3 may have broad potential indications in inflammation and pain management, which we plan to explore in future Phase II clinical testing."

The Company had total consolidated revenues of $228,000 for the three months ended June 30, 2002 and $3,855,000 for the nine months ended June 30, 2002, compared to revenues of $287,000 for the three months ended June 30, 2001 and revenues of $932,000 for the nine months ended June 30, 2001. Revenues in both fiscal 2002 and fiscal 2001 primarily reflect royalty payments from Eli Lilly and Company from the sale of Sarafem(TM).

The Company`s consolidated expenses for the three-month period ended June 30, 2002 were $5,989,000, compared to a net credit of $3,612,000 for the three-month period ended June 31, 2001 that included the reversal of Redux-related liabilities. For the nine-month period ended June 30, 2002, consolidated expenses were $16,842,000, compared to $1,797,000 for the nine-month period ended June 30, 2001. Increased expenses during the fiscal year 2002 three and nine-month periods over the comparable fiscal year 2001 periods include increased research and development expenditures for the ongoing Phase III clinical trial of trospium. Also included in expenses for fiscal year 2002 were noncash charges related to stock options.

Indevus Pharmaceuticals is a biopharmaceutical company engaged in the development and commercialization of a portfolio of products and product candidates, including multiple compounds in late-stage clinical development. The Company`s lead products under development include trospium for overactive bladder, pagoclone for panic/anxiety disorders, PRO 2000 for the prevention of infection by HIV and other sexually transmitted pathogens, dersalazine for inflammatory bowel disease, and CT-3 for pain and inflammation.

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company`s actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company`s filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: uncertainties relating to clinical trials, including the Phase III trial with trospium, regulatory approval and commercialization of our products; the early stage of products under development; need for additional funds and corporate partners, including for the development of pagoclone; history of operating losses and expectation of future losses; product liability and insurance uncertainties; risks relating to the Redux-related litigation; dependence on third parties for manufacturing and marketing; competition; risks associated with contractual arrangements; limited patent and proprietary rights; and other risks.

-0-


INDEVUS PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
For the three and nine months ended June 30, 2002 and
2001 (Amounts in thousands except per share data)
(Unaudited)

Three months ended Nine months ended
June 30, June 30,
2002 2001 2002 2001

Total revenues $ 228 $ 287 $ 3,855 $ 932

Costs and expenses:
Cost of revenues 55 70 978 200
Research and development 4,210 1,461 9,957 3,660
General and administrative 1,724 2,337 5,907 6,035
Product withdrawal -- (7,480) -- (8,098)
------ ------ ------ ------
Total costs and expenses 5,989 (3,612) 16,842 1,797
------ ------ ------ ------

Income (loss) from operations (5,761) 3,899 (12,987) (865)

Investment income, net 234 405 760 1,478
Impairment of equity
securities (487) -- (487) --
Loss on equity securities -- -- -- (43)
Minority interest (1) (4) (55) (12)
------ ------ ------ ------
Income (loss) before
cumulative effect of
change in accounting
principle (6,015) 4,300 (12,769) 558
Cumulative effect of change
in accounting principle -- -- -- (10,000)
------ ------ ------ ------
Net income (loss) $(6,015) $ 4,300 $(12,769) $(9,442)
====== ====== ====== ======
Income (loss) per common
share - basic and diluted:
Basic:
Income (loss) before
cumulative effect of
change in accounting
principle $ (0.13) $ 0.10 $ (0.28) $ 0.01
Cumulative effect of
change in accounting
principle -- -- -- (0.23)
------ ------ ------ ------
Net income (loss) $ (0.13) $ 0.10 $ (0.28) $ (0.22)
====== ====== ====== ======
Diluted:
Income (loss) before
cumulative effect of
change in accounting
principle $ (0.13) $ 0.09 $ (0.28) $ 0.01
Cumulative effect of
change in accounting
principle -- -- -- (0.22)
------ ------ ------ ------
Net income (loss) $ (0.13) $ 0.09 $ (0.28) $ (0.21)
====== ====== ====== ======

Weighted average common shares outstanding:
Basic 46,431 42,970 45,583 42,843
====== ====== ====== ======
Diluted 46,431 46,836 45,583 45,085
====== ====== ====== ======



INDEVUS PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands)
(Unaudited)

June 30, Sept. 30,
2002 2001

Cash, cash equivalents and marketable securities $ 46,443 $ 32,171
Other assets 2,094 2,746
------ ------
Total assets $ 48,537 $ 34,917

Current liabilities 6,286 6,160
Minority interest 98 97

Capital 306,215 279,953
Accumulated deficit (264,062) (251,293)
------- -------
Total stockholders` equity 42,153 28,660
------- -------
Total liabilities and stockholders` equity $ 48,537 $ 34,917
======= =======



--------------------------------------------------------------------------------
Contact:
Indevus Pharmaceuticals
Michael W. Rogers, 781/861-8444
or
William B. Boni, 781/402-3410


Email this story - Most-emailed articles - Most-viewed articles

[Wallgrekk]

Seit Wochen langsam, aber
sicher bergauf!
Ein tolles Investment weiterhin!!!

[Wallgrekk]

Habe mir heute
wieder mal ein paar Indevus gekauft!